ãã³ã·ã«ããã¢å¤§å¦ãAmos B. Smith, III 㨠Carlo Ballatore ãã®å ±å [è«æ]ã ã·ã¯ããã³ã¿ã³-1,3-ã¸ãªã³ãã«ã«ãã³é ¸ã¨åç¨åº¦ã® pKa ããã¤ãã¨ã¯å¤ãããç¥ããã¦ãã¾ããããããåµè¬åå¦ã§ã«ã«ãã³é ¸ç価ä½ã¨ãã¦ä½¿ããããã¨ã¯ããã¾ã§ãªãã£ãã¨ã®ãã¨ãä¸å³ã«ç¤ºãããã«å®éã« pKa ã logP ã¯ããªãä¼¼éã£ã¦ãã¾ããã¾ããããè¦ãã¨ã«ã«ãã³é ¸ã®ãããã¼ã°ã§ãããã è«æã§ã¯ãthromboxane A2 prostanoid (TP) receptor antagonist ã®ã«ã«ãã³é ¸é¨åãã·ã¯ããã³ã¿ã³-1,3-ã¸ãªã³ã«å¤æãããã®ããã·ã¯ããã³ã¿ã³ç°ä¸ã«ããã«ç½®æåºãå°å ¥ãããã®ãªã©ãåæãã¦æ´»æ§ãè©ä¾¡ãã¦ãã¾ããæ±åãå«ãã代è¬ãªã© ADMET ã«é¢ããè¨è¿°ãè¦å½ãããªãã£ãã®ãå°ãæ®å¿µã§ãããã«ã«ãã³é ¸ã®çç©å¦çç価ä½ã¨ãã¦è©¦ãã¦ã¿ã¦
{{#tags}}- {{label}}
{{/tags}}